scispace - formally typeset
A

Arunaloke Chakrabarti

Researcher at Post Graduate Institute of Medical Education and Research

Publications -  471
Citations -  19970

Arunaloke Chakrabarti is an academic researcher from Post Graduate Institute of Medical Education and Research. The author has contributed to research in topics: Medicine & Aspergillosis. The author has an hindex of 59, co-authored 391 publications receiving 13420 citations.

Papers
More filters
Journal ArticleDOI

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Andrew J. Ullmann, +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Journal ArticleDOI

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Oliver A. Cornely, +79 more
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Journal ArticleDOI

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

TL;DR: These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis and strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
Journal ArticleDOI

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

TL;DR: A group of experts convened to develop clinical, radiological and microbiological guidelines for the management of chronic pulmonary aspergillosis concluded that long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression.